Compare GBX & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | ALMR |
|---|---|---|
| Founded | 1974 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1996 | 2026 |
| Metric | GBX | ALMR |
|---|---|---|
| Price | $46.00 | $27.96 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 401.9K | 200.0K |
| Earning Date | 04-07-2026 | N/A |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 28.02 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $3,240,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.74 | N/A |
| P/E Ratio | $21.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.23 | $21.58 |
| 52 Week High | $59.19 | $29.43 |
| Indicator | GBX | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 61.63 |
| Support Level | $45.43 | $23.69 |
| Resistance Level | $48.66 | $29.06 |
| Average True Range (ATR) | 1.48 | 1.66 |
| MACD | -0.50 | 0.27 |
| Stochastic Oscillator | 3.85 | 77.17 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.